Full-Time

Senior Scientist

RNA Rewriter for Hematopoietic Stem Cells

Posted on 1/23/2025

Tessera Therapeutics

Tessera Therapeutics

201-500 employees

Develops gene editing technology for genetic medicine

No salary listed

Senior

Cambridge, MA, USA

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD with 5+ years of relevant academic or industrial research experience.
  • Extensive experience in in vitro and in vivo manipulation and analysis of HSC.
  • Extensive experience with multicolor FACS isolation of HSC and relevant hematopoietic populations.
  • Proficient with various NGS techniques including amplicon sequencing, and sc sequencing.
  • Quick learner, critical mind, and team player, comfortable in a fast-paced environment.
  • Strong attention to detail with the capability to work on multiple projects simultaneously.
Responsibilities
  • Designing and executing in vivo validation of selected payloads in mice and NHP.
  • Processing of primary bone marrow samples, including mouse, human and NHP origin, including multicolor flow cytometry and FACS to sort hematopoietic populations of relevance.
  • NGS libraries preparation and analysis of editing outcomes.
  • Design and execution of in vitro and in vivo experiments aimed at establishing HSC properties (fitness, multilineage differentiation) after editing.
  • Working independently and as part of a team to design, plan, execute and troubleshoot complex experiments that support Tessera’s research efforts for the development of RNA gene writers for Hematopoietic Stem Cells (HSCs).
  • Designing and testing iterations of RNA gene writers and templates in vitro on primary human HSC using electroporation or LNP transfection.
  • Execution of IND-enabling experiments in vivo aimed at validating efficacy and safety of drug products in primary bone marrow samples from mice, human and NHP origin.
  • Documenting, presenting, and communicating scientific findings to stakeholders.
Desired Qualifications
  • Previous experience with optimization of genome editing technologies for use in stem cells and in vivo models of sickle cell disease.

Tessera Therapeutics focuses on genetic medicine through its Gene Writing technology, which enables precise modifications to the human genome. This technology allows for permanent changes in genetic material across various cell types, aiming to cure diseases at their source. Tessera's Gene Writing platform can perform both small and large genetic alterations, making it applicable to a wide range of genetic disorders. The company collaborates with research institutions, pharmaceutical companies, and healthcare providers to develop new treatments. Unlike many competitors, Tessera's unique approach to genetic alteration positions it as a leader in the biotechnology sector. The goal of Tessera Therapeutics is to advance its Gene Writing technology to effectively cure genetic diseases by rewriting the genetic code.

Company Size

201-500

Company Stage

Series C

Total Funding

$532.7M

Headquarters

Cambridge, Massachusetts

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Secured $300 million in Series C financing in 2022.
  • Partnership with Gates Foundation for sickle cell disease treatment.
  • Located in Boston, a leading biotech hub.

What critics are saying

  • Departure of key executive Dr. Ranade may impact strategy.
  • High competition in Boston's biotech sector.
  • Potential over-reliance on Gates Foundation funding.

What makes Tessera Therapeutics unique

  • Pioneering Gene Writing technology for precise genome alterations.
  • Offers potential cures by rewriting genetic code at the source.
  • Versatile platform targeting a wide range of genetic disorders.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↓ -2%

2 year growth

↑ 4%
Market Wire News
Apr 15th, 2025
DYN - Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

Dr. Ranade joins Dyne, effective immediately, from Tessera Therapeutics, where he was senior vice president of corporate development, leading strategy and business development, and was member of the executive team.

DDW Online
Dec 18th, 2024
Investment to develop curative in vivo genetic treatment for sickle cell disease

Tessera Therapeutics, a biotech developing a new approach to genome engineering, has entered into an agreement with the Bill & Melinda Gates Foundation to jointly fund the company's in vivo programme for sickle cell disease (SCD).

BioSpace
Dec 18th, 2024
Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease

Tessera is developing Gene Writers(TM) for SCD designed to enable a true correction of the sickle mutation to wild-type with one-time intravenous administration in vivo, without the need for complex stem cell mobilization or toxic chemotherapy conditioning.

The Manila Times
Dec 18th, 2024
Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease

Tessera Therapeutics receives investment to develop curative in vivo genetic treatment for sickle cell disease.

Bizjournals
Dec 18th, 2024
Gates Foundation invests $50M in Tessera

The Bill & Melinda Gates Foundation is investing up to $50 million in Tessera Therapeutics to support its development of in-vivo genetic medicines for sickle cell disease. Tessera aims to offer a one-time intravenous treatment that avoids the need for high-dose chemotherapy and complex stem cell mobilization, unlike existing ex-vivo therapies. Tessera, founded by Flagship Pioneering, previously raised $230 million in Series B financing in 2021 and $300 million in 2022.

INACTIVE